In a retrospective study of bleeding patients in cardiac surgery, Cappabianca et al. \[[@CR1]\] observed that the use of prothrombin complex concentrate (PCC) compared with fresh-frozen plasma (FFP) was associated with a higher risk of postoperative renal complications. In the unadjusted comparison, acute kidney injury (AKI) incidence was significantly higher in the PCC group, and use of PCC was an independent predictive factor of AKI development and the need for renal replacement therapy in the propensity-adjusted multivariate analysis. Since prothrombotic effects of PCC are unlikely as the underlying mechanism because an increase of thromboembolic events was not observed in the study, the authors speculate that volume excess given with FFP and a more hypovolemic balance with PCC in the context of bleeding patients could have exerted a protective effect on kidney function in the FFP group. Interestingly, in the PCC group, use of inotropes was significantly lower than in the FFP group (*p* = 0.007) \[[@CR1]\]. This may have contributed to the observed difference in renal risk, since a recent meta-analysis on perioperative hemodynamic management associated inotropic drug use with a reduction in the incidence of postoperative AKI (odds ratio = 0.52, 95 % confidence interval = 0.34--0.80, *p* = 0.003, 14 studies, *n* = 1634 patients; included were two studies in cardiac surgery, *n* = 433 patients) \[[@CR2]\]. The observed association of PCC use with higher risk of AKI may therefore be due to unknown confounders in this observational propensity score-matched analysis \[[@CR3]\] rather than due to direct pharmacological effects of PCC.
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See related research by Cappabianca et al., <http://www.ccforum.com/content/20/1/5>
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We read with great interest this letter from Wiedermann regarding our recent study \[[@CR1]\] investigating the safety and efficacy of PCC as first-line treatment in bleeding after cardiac surgery. In our study, we observed an increased incidence of AKI and renal replacement therapy in the group of patients receiving PCC compared with those receiving FFP (31.3 % vs. 23.4 %, *p* = 0.01 and 3.1 % vs. 1.2 %, *p* = 0.037, respectively). We originally speculated that embolic events and especially the hypovolemia accompanying PCC use could have explained the observed correlation with renal dysfunction. Wiedermann underlined that the lower AKI rate observed in the FFP group could have been related to the high rate of inotropes (protective confounders) encountered in the same patient group rather than the hypovolemic balance following PCC use. We agree that postoperative AKI is a consequence of an interplay of different pathophysiologic mechanisms, and it remains distinctly possible that inotropes may protect against AKI, ameliorating blood pressure and perfusion \[[@CR4]\]. In addition, our study could also have reflected the inherited inability of observational investigations in proving causality. However, the correlation between inotropes and AKI is disputed \[[@CR5]\], and even in the meta-analysis by Prowle and colleagues \[[@CR2], [@CR5]\] the exact AKI contribution of inotropes and volume fluid resuscitation was difficult to ascertain. Nevertheless, our study did not show any significant difference between the rate of inotropes in the PCC and FFP propensity matched groups (odds ratio = 0.74, 95 % confidence interval = 0.50--1.08) \[[@CR1]\].
